

First synthesis of picealactone C. A new route toward taxodione-related terpenoids from abietic acid

Enrique Alvarez-Manzaneda,^{a,*} Rachid Chahboun,^a Eduardo Cabrera,^a Esteban Alvarez,^a Ramón Alvarez-Manzaneda,^b Mohammed Lachkar^c and Ibteissam Messouri^c

^aDepartamento de Química Orgánica, Facultad de Ciencias, Instituto de Biotecnología, Universidad de Granada, 18071 Granada, Spain

^bDepartamento de Química Orgánica, Facultad de Ciencias, Universidad de Almería, 04120 Almería, Spain

^cLaboratoire d'Ingenierie des Materiaux Organometalliques et Moleculaires, Faculté des Sciences, Université Sidi Mohammed Ben Abdellah, BP 1786 (Atlas), 30000 Fès, Morocco

Received 10 November 2006; revised 1 December 2006; accepted 4 December 2006

Available online 22 December 2006

Abstract—A new route to 12-hydroxyabietic acid (**10**) and related compounds from abietic acid (**12**), via acetoxyalcohol **15**, is reported. Utilizing this, the first synthesis of picealactone C (**5**) was achieved. The synthesis of natural 12-hydroxydehydroabietic acid (**8**), 18-hydroxyferruginol (**9**) and methyl 12 α -hydroxyabietate (**11**) is also reported.


© 2006 Elsevier Ltd. All rights reserved.

Abietane diterpenes constitute an important group of secondary metabolites that are widely found in nature. Continuing research into the isolation of such compounds reveals their considerable structural diversity; moreover, many of them present interesting biological activities. Among these a number of variously oxidized compounds bearing oxygenated functions on the C ring should be emphasized. Representative examples of the latter are taxodione (**1**)¹ and salvinolone (**2**),² which are active against methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant *Enterococcus* (VRE), two bacteria that are increasingly found in hospitals worldwide. Other significant oxidized abietane diterpenes are 6 α -hydroxysugiol (**3**), which strongly

inhibits various human tumors and oncogen transformed cells,³ and the antileishmanial 12-deoxyroyleanone (**4**).⁴

In previous papers, we reported new procedures to introduce the oxygenated function on the abietane skeleton C-14, which we utilized to prepare **4** from abietic acid (**12**)⁵ and on C-15, which allowed us to synthesize some bioactive terpenoids and lactones **6–7**.⁶

Continuing our studies on the abietane C ring functionalization, we are now interested in investigating new methods to place the oxygenated function on C-12,



Keywords: Enantiospecific synthesis; Abietane diterpenoids; Lactones.

* Corresponding author. Tel./fax: +34 958 24 80 89; e-mail: eamr@ugr.es

which will enable the synthesis of bioactive compounds such as **1–3** and related abietic acid derivatives, including picealactone **C** (**5**)⁷ and 12-hydroxydehydroabietic acid (**8**), recently described as a new natural product.⁸ Only two procedures to synthesize 12-hydroxyabietic acid derivatives from abietic acid (**12**), based on the preparation of an iron complex⁹ and on the electrochemical oxidation of the corresponding methyl ester,¹⁰ have been reported. Other process, based on the solvolysis of the products resulting from the treatment of methyl abietate with *N*-bromosuccinimide, affords the target compound in a very low yield.¹¹ 12-Hydroxydehydroabietic acid (**8**) derivatives have been synthesized by electrophilic substitution via the Baeyer–Villiger oxidation of the corresponding 12-acetyl derivative obtained after Friedel–Crafts acylation, which takes place in a moderate yield.^{12,13}


We planned a strategy to prepare methyl 12 α -hydroxyabietate (**11**) based on the allylic displacement of a suitable X leaving group in an intermediate **A**, which results from the regioselective HY elimination of 13,14-adduct **B** (Scheme 1).

When monoacetate **15** was treated with thionyl chloride and triethylamine in dichloromethane at $-78\text{ }^\circ\text{C}$, and the reaction was quenched by adding aqueous sodium bicarbonate, methyl 12 α -chloroabietate (**16**) was obtained in a high yield. This compound could be formed via intermediate **I** through an $\text{S}_{\text{N}}2'$ process. The chloride **16** was transformed into alcohol **11**, a natural diterpene found in some *Abies* and *Pine* species,¹⁵ in a high yield by treating with sodium bicarbonate in water–dimethylsulfoxide. The C-12 configuration of compounds **16** and **11** was unequivocally established on the basis of the H-12 pattern in the ^1H NMR spectrum of these compounds; this proton appears as a triplet ($J = 2.9\text{ Hz}$) at 4.75 for chloride **16** and at 4.20 ppm for alcohol **11**. It should be noted that the ^1H NMR spectrum of the


C12 β -OH epimer of **11** showed a double doublet ($J = 10.0, 4.7\text{ Hz}$) at 4.41 ppm for H-12.¹⁵ The transformation of **16** into **11** should take place through a $\text{S}_{\text{N}}1$ process; the retention of the configuration on C-12 can be attributed to the most favorable α -attack of nucleophile on the intermediate allyl cation, due to the presence of the β -axial methyl group on C-10 (Scheme 2).

The 12-hydroxydehydroabietic acid derivatives were then obtained via dienone **17**.¹⁶ The oxidation of alcohol **11** to ketone **17** was not a trivial task; usual oxidizing reagents, such as pyridinium chlorochromate or benzeneseleninic anhydride, which have been successfully utilized with similar structures,⁹ mainly gave the dehydration product. However, the treatment of alcohol **11** with pyridinium dichromate gave the desired compound **17** in an acceptable yield. Alternatively, dienone **17** was obtained in a high yield from chloride **16**, after reaction with sodium bicarbonate in freshly distilled dimethyl sulfoxide (Scheme 3). The isomerization of dienone **17** to phenol **18** was achieved by refluxing an acetic acid solution in the presence of sulfuric acid.¹⁷ 12-Hydroxy-dehydroabietic acid (**8**), recently isolated from the stem bark of *Picea glehni*,⁸ was obtained after saponification of ester **18**, which by reduction with lithium aluminum hydride gave the also natural 18-hydroxyferruginol (**9**), first isolated from *Torreya nucifera*.¹⁸


Next, the preparation of picealactone **C** (**5**), a new diterpene recently isolated from *Picea morrisonicola*,⁷ was undertaken. After protecting the phenolic hydroxyl group of ester **18** as acetate, the 7-oxo group of the target molecule was introduced, obtaining ketoester **20**, and then the elaboration of the enol–lactone moiety of compound **5** was tackled. The same methodology previously reported by the present authors for synthesizing lactones **6** and **7** was essayed for this purpose.⁶ However, the treatment of a solution of acetate **20** and potassium *tert*-butoxide in *tert*-butanol with oxygen produced



Scheme 1.



Scheme 2. Reagents and conditions: (i) Refs. 6 and 14; (ii) Ac_2O , pyridine, rt, 10 h (95%); (iii) SOCl_2 , NEt_3 , CH_2Cl_2 , $-78\text{ }^\circ\text{C}$, 20 min; aq NaHCO_3 (80%) and (iv) NaHCO_3 , DMSO, H_2O , rt, 15 h (95%).



Scheme 3. Reagents and conditions: (i) PDC, CH₂Cl₂, rt, 45 min (60%); (ii) NaHCO₃, DMSO, rt, 15 h (96%); (iii) H₂SO₄, AcOH, reflux, 12 h (85%); (iv) K₂CO₃, MeOH, reflux, 12 h (92%); (v) LiAlH₄, THF, rt, 12 h (93%); (vi) AcONa, Ac₂O, reflux, 2 h (91%); (vii) Na₂CrO₄ (2 equiv), AcONa, AcOH, benzene, reflux, 18 h (90%); (viii) O₂, *t*-BuOK, *t*-BuOH, rt, 2 h (95%); (ix) TBSCl, imidazole, DMF, rt, 12 h (90%); (x) MeI, K₂CO₃, acetone, reflux, 4 h (95%); (xi) DCC, THF, rt, 30 min (75% from **23**); (xii) HBr, AcOH, 40 °C, 1 h and (xiii) DCC, THF, rt, 30 min (71% from **25**).

only deacetylation, affording ketophenol **21**. This product also resulted when silylderivative **22** was subjected to the same reaction conditions. These results could be attributed to the electron attractive effect of the carbonyl group bearing C-7. Our objective was achieved by utilizing the corresponding methyl ether. Thus, the oxidation of compound **23** gave a 1:1 mixture of diosphenol **24** and lactone **25**, which after treatment with dicyclohexylcarbodiimide afforded lactone **25** as the only product. Finally, the treatment of a solution of methoxyderivative **25** in acetic acid with hydrobromic acid gave a 1:2 mixture of diosphenol **26** and picealactone (**5**), which was completely converted into the desired lactone **5**, by treating with DCC. The spectroscopic properties of compound **5**¹⁹ were identical to those reported in the literature.⁷

In summary, a new route to 12-hydroxyabietic acid derivatives from abietic acid (**12**) is reported. The key step involves an S_N2' process on the allylic acetate which results from the dehydration of acetoxyalcohol **15**. Utilizing this methodology, the first synthesis of picealactone C (**5**) has been accomplished.

Acknowledgement

The authors thank Ministerio de Ciencia y Tecnología (Project CTQ2006-12697) for financial support.

References and notes

- Kupchan, S. M.; Karim, A.; Marcks, C. *J. Org. Chem.* **1969**, *34*, 3912–3918; Kupchan, S. M.; Karim, A.; Marcks, C. *J. Am. Chem. Soc.* **1968**, *90*, 5923–5924.
- (a) Gil, R. R.; Cordell, G. A. *J. Nat. Prod.* **1994**, *57*, 181–185; (b) Lin, L. Z.; Blasko, G.; Cordell, G. A. *Phytochemistry* **1989**, *28*, 177–181.
- Son, K.-H.; Oh, H.-M.; Choi, S.-K.; Han, D.-C.; Kwon, B.-M. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 2019–2021.
- Achenbach, H.; Walbel, R.; Nkonya, M. H. H.; Weenen, H. *Phytochemistry* **1992**, *31*, 3781–3784.
- Alvarez-Manzaneda, E. J.; Chahboun, R.; Bentaleb, F.; Cabrera Torres, E.; Alvarez, E.; Haidour, A.; Ramos López, J. M.; Alvarez-Manzaneda, R.; El Houssame, S. *Synlett* **2004**, 2701–2704.
- Alvarez-Manzaneda, E. J.; Chahboun, R.; Guardia, J. J.; Lachkar, M.; Dahdouh, A.; Lara, A.; Messouri, I. *Tetrahedron Lett.* **2006**, *47*, 2577–2580.
- Kuo, Y. H.-H.; Yeh, M.-H.; Li, H.-C. *Chem. Pharm. Bull.* **2004**, *52*, 861–863.
- Kinouchi, Y.; Ohtsu, H.; Tokuda, H.; Nishino, H.; Matsunaga, S.; Tanaka, R. *J. Nat. Prod.* **2000**, *63*, 817–820.
- Haslinger, E.; Michl, G. *Tetrahedron Lett.* **1988**, *29*, 5751–5754.
- Takemura, S.; Matsubara, Y.; Obata, T.; Zhou, Z.; Fujiwara, Y. *Nippon Kagaku Kaishi* **1994**, 545–550.
- Sircar, J. C.; Fischer, G. S. *J. Org. Chem.* **1970**, *35*, 3090–3093.
- Cambie, R. C.; Franich, R. A. *Aust. J. Chem.* **1971**, *24*, 117–134.
- Akita, H.; Oishi, T. *Chem. Pharm. Bull.* **1981**, *29*, 1567–1579.
- Okawara, H.; Nakai, H.; Ohno, M. *Tetrahedron Lett.* **1982**, *23*, 1087–1090.
- Barrero, A. F.; Sánchez, J. F.; Alvarez-Manzaneda, E. J.; Muñoz Dorado, M.; Haidour, A. *Phytochemistry* **1991**, *30*, 593–597, and references cited therein.
- Prinz, S.; Mullner, U.; Heilmann, J.; Winkelmann, K.; Sticher, O.; Haslinger, E.; Hufner, A. *J. Nat. Prod.* **2002**, *65*, 1530–1534.
- Moore, R. N.; Lawrence, R. V. *J. Am. Chem. Soc.* **1959**, *81*, 458–460.
- (a) Fukushima, I.; Sayama, Y.; Kyogoku, K.; Murayama, H. *Agric. Biol. Chem.* **1968**, *32*, 1103–1107; (b) Harrison, L. J.; Asakawa, Y. *Phytochemistry* **1987**, *26*, 1211–1212.
- Spectroscopic properties of natural terpenoids (**5**, **8**, **9** and **11**) were identical to those reported in the literature. All

new compounds were fully characterized spectroscopically and had satisfactory high resolution mass spectroscopy data. Selected data:

Compound 11: ^1H NMR (CDCl_3 , 300 MHz) δ : 0.74 (3H, s), 0.99 (3H, d, $J = 6.8$ Hz), 1.03 (3H, d, $J = 6.8$ Hz), 1.18 (3H, s), 2.25 (1H, br d, $J = 12.4$ Hz), 2.38 (1H, h, $J = 6.8$ Hz), 3.56 (3H, s), 4.20 (1H, t, $J = 2.9$ Hz), 5.45 (1H, m), 5.77 (1H, s). ^{13}C NMR (CDCl_3 , 75 MHz) δ : 38.1 (C-1), 18.1 (C-2), 37.2 (C-3), 46.6 (C-4), 45.1 (C-5), 25.9 (C-6), 124.3 (C-7), 134.5 (C-8), 43.6 (C-9), 34.1 (C-10), 26.0 (C-11), 66.4 (C-12), 144.1 (C-13), 125.6 (C-14), 32.6 (C-15), 21.7 (C-16), 22.4 (C-17), 178.9 (C-18), 16.9 (C-19), 14.4 (C-20), 51.9 (COOCH_3).

Compound 16: ^1H NMR (CDCl_3 , 300 MHz) δ : 0.83 (3H, s), 1.04 (3H, d, $J = 6.8$ Hz), 1.12 (3H, d, $J = 6.8$ Hz), 1.25 (3H, s), 2.42 (1H, h, $J = 6.8$ Hz), 2.55 (1H, m), 3.66 (3H, s), 4.75 (1H, t, $J = 2.9$ Hz), 5.56 (1H, m), 5.90 (1H, s). ^{13}C NMR (CDCl_3 , 75 MHz) δ : 37.6 (C-1), 17.7 (C-2), 36.7 (C-3), 46.1 (C-4), 44.5 (C-5), 25.6 (C-6), 125.1 (C-7), 133.6 (C-8), 43.9 (C-9), 33.6 (C-10), 31.5 (C-11), 58.4 (C-12), 141.9 (C-13), 126.5 (C-14), 31.6 (C-15), 21.1 (C-16), 22.2 (C-17), 178.2 (C-18), 16.7 (C-19), 14.4 (C-20), 51.6 (COOCH_3).

Compound 18: ^1H NMR (CDCl_3 , 300 MHz) δ : 1.19 (6H, d, $J = 5.1$ Hz), 1.22 (3H, s), 1.26 (3H, s), 2.17 (1H, br d, $J = 9.3$ Hz), 2.20 (1H, br d, $J = 8.1$ Hz), 2.80 (2H, m), 3.13 (1H, h, $J = 5.1$ Hz), 3.66 (3H, s), 6.63 (1H, s), 6.81 (1H, s). ^{13}C NMR (CDCl_3 , 75 MHz) δ : 36.7 (C-1), 18.6 (C-2), 38.1 (C-3), 47.7 (C-4), 44.9 (C-5), 21.9 (C-6), 29.3 (C-7), 126.8 (C-8), 147.8 (C-9), 37.0 (C-10), 110.8 (C-11), 151.1 (C-12), 132.0 (C-13), 126.7 (C-14), 26.8 (C-15), 22.6 (C-16), 22.8 (C-17), 179.4 (C-18), 25.1 (C-19), 16.5 (C-20), 51.9 (COOCH_3).

Compound 19: ^1H NMR (CDCl_3 , 300 MHz) δ : 1.19 (6H, d, $J = 5.1$ Hz), 1.20 (3H, s), 1.26 (3H, s), 2.19 (1H, br d, $J = 9.3$ Hz), 2.30 (3H, s), 2.87 (2H, m), 2.88 (1H, h, $J = 5.1$ Hz), 3.66 (3H, s), 6.82 (1H, s), 6.93 (1H, s). ^{13}C NMR (CDCl_3 , 75 MHz) δ : 36.6 (C-1), 18.5 (C-2), 37.9 (C-3), 47.6 (C-4), 44.5 (C-5), 21.6 (C-6), 29.4 (C-7), 132.9 (C-8), 146.2 (C-9), 37.0 (C-10), 117.8 (C-11), 148.1 (C-12), 137.0 (C-13), 127.0 (C-14), 27.1 (C-15), 22.9 (C-16), 23.1 (C-17), 179.0 (C-18), 25.0 (C-19), 16.4 (C-20), 169.9 (OCOCH_3), 20.9 (OCOCH_3), 51.9 (COOCH_3).

Compound 20: ^1H NMR (CDCl_3 , 300 MHz) δ : 1.21 (3H, d, $J = 6.9$ Hz), 1.22 (3H, d, $J = 6.9$ Hz), 1.27 (3H, s), 1.34 (3H, s), 2.26 (1H, br d, $J = 9.1$ Hz), 2.33 (1H, m), 2.34 (3H, s), 2.72 (2H, m), 2.99 (1H, h, $J = 6.9$ Hz), 3.65 (3H, s), 6.99 (1H, s), 7.99 (1H, s). ^{13}C NMR (CDCl_3 , 75 MHz) δ : 37.0 (C-1), 18.1 (C-2), 37.7 (C-3), 46.7 (C-4), 43.6 (C-5), 36.4 (C-6), 197.4 (C-7), 138.7 (C-8), 152.7 (C-9), 37.4 (C-10), 117.6 (C-11), 154.3 (C-12), 128.9 (C-13), 126.6 (C-14), 27.3 (C-15), 22.7 (C-16), 22.8 (C-17), 177.7 (C-18), 23.6 (C-19), 16.4 (C-20), 169.1 (OCOCH_3), 21.0 (OCOCH_3), 52.2 (COOCH_3).

Compound 22: ^1H NMR (CDCl_3 , 300 MHz) δ : 0.26 (3H, s), 0.28 (3H, s), 1.01 (9H, s), 1.19 (3H, d, $J = 6.9$ Hz), 1.20 (3H, d, $J = 6.9$ Hz), 1.24 (3H, s), 1.32 (3H, s), 2.19 (1H, br d, $J = 12.8$ Hz), 2.68 (2H, m), 3.15 (1H, h, $J = 6.9$ Hz), 3.64 (3H, s), 6.69 (1H, s), 7.88 (1H, s). ^{13}C NMR (CDCl_3 , 75 MHz) δ : 37.2 (C-1), 18.3 (C-2), 37.7 (C-3), 46.8 (C-4), 44.1 (C-5), 36.6 (C-6), 197.2 (C-7), 137.7 (C-8), 154.9 (C-9), 37.4 (C-10), 112.7 (C-11), 158.5 (C-12), 124.7 (C-13), 126.3 (C-14), 26.6 (C-15), 22.6 (C-16), 22.7 (C-17), 177.9 (C-18), 23.7 (C-19), 16.5 (C-20), -3.8 (3H, Me-Si), -4.0 (3H, Me-Si), 25.8 (Me, *t*-Bu), 29.8 (C, *t*-Bu) 52.2 (COOCH_3).

Compound 23: ^1H NMR (CDCl_3 , 300 MHz) δ : 1.20 (6H, d, $J = 6.9$ Hz), 1.27 (3H, s), 1.34 (3H, s), 1.60–1.90 (5h, m), 2.33 (2H, m), 2.70 (2H, m), 3.25 (1H, h, $J = 6.9$ Hz), 3.64 (3H, s), 3.93 (3H, s), 6.75 (1H, s), 7.89 (1H, s). ^{13}C NMR (CDCl_3 , 75 MHz) δ : 37.1 (C-1), 18.3 (C-2), 37.7 (C-3), 46.8 (C-4), 44.1 (C-5), 36.5 (C-6), 197.1 (C-7), 135.6 (C-8), 155.6 (C-9), 37.8 (C-10), 104.3 (C-11), 161.8 (C-12), 124.1 (C-13), 125.8 (C-14), 26.6 (C-15), 22.4 (C-16), 22.6 (C-17), 177.8 (C-18), 23.6 (C-19), 16.5 (C-20), 55.5 (OCH_3), 52.2 (COOCH_3).

Compound 5: ^1H NMR (CDCl_3 , 300 MHz) δ : 1.31 (6H, d, $J = 6.9$ Hz), 1.59 (3H, s), 1.62 (3H, s), 2.50 (1H, br d, $J = 13.2$ Hz), 3.29 (1H, h, $J = 6.9$ Hz), 3.96 (3H, s), 7.19 (1H, s), 7.98 (1H, s). ^{13}C NMR (CDCl_3 , 75 MHz) δ : 42.7 (C-1), 19.6 (C-2), 36.5 (C-3), 47.8 (C-4), 146.9 (C-5), 145.7 (C-6), 173.8 (C-7), 124.9 (C-8), 152.6 (C-9), 40.1 (C-10), 108.2 (C-11), 161.9 (C-12), 137.1 (C-13), 124.7 (C-14), 27.4 (C-15), 22.7 (C-16), 22.7 (C-17), 180.8 (C-18), 21.4 (C-19), 24.7 (C-20), 56.3 (OCH_3).